Get started
Mind Medicine (MindMed) Inc.Mind Medicine (MindMed) Inc.Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc.

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptionsETFs

Trade ideas

Mind Medicine (MindMed) Inc. (MNMD) Advances Psychedelic DrugsMind Medicine (MindMed) Inc. (MNMD) is a clinical-stage biopharmaceutical company developing psychedelic-inspired medicines to treat brain health disorders such as anxiety, depression, and addiction. By combining neuroscience, digital biomarkers, and precision dosing, MindMed aims to redefine mental health treatment. The company’s growth is fueled by clinical trial progress, growing acceptance of psychedelic therapies, and rising global demand for innovative psychiatric care solutions. On the chart, a confirmation bar with rising volume highlights bullish sentiment. The price has entered the momentum zone after breaking above the .236 Fibonacci level. A trailing stop can be placed just below this Fibonacci mark using the Fibonacci snap tool, helping traders secure profits while leaving room for continued upside potential.
NASDAQ:MNMDLong
by traderspro_charts
MNMD – MindMed | Bullish Setup in Psychedelic Biotech SectorMind Medicine Inc. NASDAQ:MNMD is emerging as a key player in the psychedelic-inspired therapeutics space, developing next-gen treatments for mental health and neurological disorders such as anxiety and addiction. 🔬 Clinical Highlights Lead candidate MM120 (a refined LSD formulation) is in three pivotal Phase 3 trials targeting GAD (Generalized Anxiety Disorder) and MDD (Major Depressive Disorder). Strong Phase 2b efficacy data backs the current trial progress. Cash runway through 2027 supports continued development without immediate capital pressure. ⚖️ Regulatory & Social Momentum Growing bipartisan political support—notably from U.S. lawmakers pushing for veteran access to psychedelic therapy. Institutional backing and changing public perception could accelerate regulatory approval and market entry. 🧩 Strategic Execution New leadership: Brandi Roberts (CFO) and Matt Wiley (CCO) add commercial expertise. Equity grants and talent acquisition efforts signal serious intent to scale operations for potential commercialization. 📈 Technical View Bullish bias above $9.50–$10.00 Target range: $14.00–$15.00 MNMD is aligning technical setup with strong fundamental and macro tailwinds. This makes it a name to watch closely in the psychedelic biotech space.
NASDAQ:MNMDLong
by Richtv_official
MNMD bulls looking to take out key resistanceMNMD solid move back towards thd $10 range. Key resitstance tomorrow will be the daily lower high from Monday as bulls have regrouped after the rejection from 10.49 and look to want to break through this long term area of resistance once and for all. Hourly uptrend will be my guide as to knowing when this move has topped out. I publish regular technical analysis of the psychedelic sector. Be sure to like and follow to not miss an important update!
NASDAQ:MNMDLong
by McGuireTO
MNMD Weekly consolidation underway. What will earnings do?MNMD has started weekly consolidation by 2c right as ATAI and possibly CMPS end their weekly consolidations. Earnings after hours tonight had no real effect on the charts, so here are the levels I'm looking at into tomorrow. Click to watch the free video for more details I provider regular chart analysis of the psychedelics sector. Be sure to Like and Follow, and Subscribe to future updates so you don't miss a post! Support: 8.94, 8.79 Resistance: 9.40, 9.44
NASDAQ:MNMDLong
by McGuireTO
2
MNMD on the cusp of a lower volume nodeMNMD closed July 8th with the most bullish candle since May 19th, finally giving us a convining break of the daily equilibrium, and resulting in a gap up and run this morning with another solid day up over 3%. Today's high rejected from the top of the current high volume node mentioned in my weekend video (7.80), above this there isn't much resistance until the weekly resistance doubletop at 8.21. Hourly RSI is entering into typical pullback areas over the last 6 months so we will be watching the hourly uptrend for clues on pullbacks if we are seeing healthy hourly consolidation or looking for a daily consolidation.
NASDAQ:MNMDLong
by McGuireTO
Anticipating MNMD bull break, but large overhead supply remainsMNMD is looking good on the daily chart for a bull break from it's currently daily equilibrium, but it still remains far from it's weekly and monthly resistance levels that ATAI has already cleared. I do anticipate MNMD to benefit from the GO signal from ATAI but the additional overhead supply may remain an obstacle until we get through it, either through grinding price action or a news catalyst specific to MNMD. Entry: 6.77 Stop loss: 6.27
NASDAQ:MNMDLong
by McGuireTO
1
MNMDI have owned this stock for along time and hardly ever check up, I bought last year in 2024 and still looks pretty solid around this range I avg'd in at, Its a weird play and the future is in the hands of the American government and regulations around psychedelic therapy News: Executive Changes In May 2025, MindMed appointed Brandi Roberts, CPA, as Chief Financial Officer Upcoming Event MindMed is scheduled to participate in the Jefferies Global Healthcare Conference on June 5, 2025, and will hold its Annual General and Special Meeting of Shareholders on June 12, 2025.
NASDAQ:MNMDLong
by sykXBT
MNMD LONGBreakout, CHoCH, volume supporting the move, 20.82 target, march Opex expiration. nothing big, I like the setup. why are we running tho?? The confirmation of Robert F. Kennedy Jr. as the head of the U.S. Department of Health and Human Services could have a positive impact on biotech stocks, particularly in the psychedelic space. RFK Jr.'s support for mental health treatments using psychedelics like those being developed by Mind Medicine (MNMD) aligns with a potential shift in policy towards chronic disease prevention and alternative therapies. Analysts believe this could boost biotech companies focused on psychedelics, such as MNMD, which saw a slight uptick in stock following his confirmation.
NASDAQ:MNMDLong
by SPYDERMARKET